Jiao Ji

1.5k total citations
23 papers, 1.0k citations indexed

About

Jiao Ji is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jiao Ji has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jiao Ji's work include Cancer Immunotherapy and Biomarkers (4 papers), Ubiquitin and proteasome pathways (4 papers) and Autophagy in Disease and Therapy (3 papers). Jiao Ji is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Ubiquitin and proteasome pathways (4 papers) and Autophagy in Disease and Therapy (3 papers). Jiao Ji collaborates with scholars based in China, United States and Canada. Jiao Ji's co-authors include Rong Deng, Xiao‐Feng Zhu, Gong-Kan Feng, Xuan Li, Yan Yu, Dandan Li, Lin Jiao, Wen-Dan Chen, Rui-Yan Wu and Hai‐Liang Zhang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jiao Ji

23 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiao Ji China 11 618 338 238 216 103 23 1.0k
T J Collard United Kingdom 17 706 1.1× 191 0.6× 373 1.6× 263 1.2× 93 0.9× 29 1.1k
Eduardo Briceño Chile 7 357 0.6× 399 1.2× 137 0.6× 129 0.6× 76 0.7× 31 736
Gregory Dyson United States 20 577 0.9× 160 0.5× 326 1.4× 304 1.4× 142 1.4× 74 1.1k
Hanxiang Zhan China 20 573 0.9× 151 0.4× 394 1.7× 420 1.9× 120 1.2× 41 1.1k
Fuqing Hu China 16 873 1.4× 196 0.6× 449 1.9× 242 1.1× 130 1.3× 20 1.3k
Estelle Saland France 18 902 1.5× 232 0.7× 329 1.4× 179 0.8× 65 0.6× 28 1.4k
Barry Jutten Netherlands 17 442 0.7× 192 0.6× 266 1.1× 209 1.0× 106 1.0× 19 804
Wei Wei Prior United States 8 644 1.0× 252 0.7× 91 0.4× 199 0.9× 147 1.4× 10 888
Guanghua Chen China 11 573 0.9× 681 2.0× 165 0.7× 116 0.5× 54 0.5× 23 1.0k

Countries citing papers authored by Jiao Ji

Since Specialization
Citations

This map shows the geographic impact of Jiao Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiao Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiao Ji more than expected).

Fields of papers citing papers by Jiao Ji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiao Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiao Ji. The network helps show where Jiao Ji may publish in the future.

Co-authorship network of co-authors of Jiao Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Jiao Ji. A scholar is included among the top collaborators of Jiao Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiao Ji. Jiao Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ji, Jiao, et al.. (2023). Study on Microfluidic Chip Flow Rate Uniformity for Cell Activity Detection. Langmuir. 39(18). 6548–6555. 4 indexed citations
2.
Pemmaraju, Naveen, Boyd Mudenda, Cunlin Wang, et al.. (2020). Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. Blood. 136(Supplement 1). 15–16. 4 indexed citations
3.
Rasco, Drew, Nehal J. Lakhani, Hengbang Wang, et al.. (2020). Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3508–3508. 6 indexed citations
4.
Tolcher, Anthony W., Hengbang Wang, Jiao Ji, et al.. (2020). Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3512–3512. 1 indexed citations
5.
Tolcher, Anthony W., et al.. (2019). Abstract A086: Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S.. Molecular Cancer Therapeutics. 18(12_Supplement). A086–A086. 3 indexed citations
6.
Ji, Jiao, Guoqiang Li, Yaqin Xu, Ai‐Quan Jia, & Qian‐Feng Zhang. (2019). Syntheses and properties of cyclometalated ruthenium(II) complexes with 1,10-phenanthroline and phenylphthalazine ligands. Zeitschrift für Naturforschung B. 74(3). 267–271. 4 indexed citations
7.
Ji, Jiao, Chong Chen, Ai‐Quan Jia, Hua‐Tian Shi, & Qian‐Feng Zhang. (2019). Syntheses, structures and photocatalytic properties of ruthenium complexes bearing L-methionine ligands. Journal of Organometallic Chemistry. 907. 121078–121078. 5 indexed citations
8.
9.
Ji, Jiao, Yan Yu, Zhi‐Ling Li, et al.. (2018). XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells. Theranostics. 8(6). 1494–1510. 46 indexed citations
10.
Xu, Rui‐Hua, Yuhong Li, Jiao Ji, et al.. (2018). A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). 2593–2593. 6 indexed citations
11.
Bai, Longchuan, Bing Zhou, Chao‐Yie Yang, et al.. (2017). Abstract 5074: Therapeutic targeting of bromodomain and extra-terminal proteins degradation in triple-negative breast cancer. Cancer Research. 77(13_Supplement). 5074–5074. 1 indexed citations
12.
Karataş, Hacer, Yangbing Li, Liu Liu, et al.. (2017). Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction. Journal of Medicinal Chemistry. 60(12). 4818–4839. 75 indexed citations
13.
Zhang, Lin, Miao‐Zhen Qiu, Ying Jin, et al.. (2015). Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.. PubMed. 8(9). 11084–91. 85 indexed citations
14.
Sun, Ting, Xuan Li, Peng Zhang, et al.. (2015). Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nature Communications. 6(1). 7215–7215. 181 indexed citations
15.
Yu, Yan, Fen Yang, Rong Deng, et al.. (2015). Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors. Oncotarget. 6(7). 5134–5146. 30 indexed citations
16.
Qin, Juan, Jiao Ji, Rong Deng, et al.. (2015). DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2. Oncotarget. 6(9). 6944–6958. 34 indexed citations
17.
Zhang, Peng, Wen-Dan Chen, Dandan Li, et al.. (2015). ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy. 11(2). 239–252. 132 indexed citations
18.
Ji, Jiao, David P. Anderson, & Xinchun Wu. (2015). Motivational Factors in Career Decisions Made by Chinese Science Museum Educators. Adult Education Quarterly. 66(1). 21–38. 9 indexed citations
19.
Yu, Yan, Zhenhua Li, Rui-Yan Wu, et al.. (2015). EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 6(19). 17491–17500. 10 indexed citations
20.
Qin, Juan, Jun Tang, Lin Jiao, et al.. (2013). A diterpenoid compound, excisanin A, inhibits the invasive behavior of breast cancer cells by modulating the integrin β1/FAK/PI3K/AKT/β-catenin signaling. Life Sciences. 93(18-19). 655–663. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T J Collard Breakdown of academic impact, for papers by Eduardo Briceño Breakdown of academic impact, for papers by Gregory Dyson Breakdown of academic impact, for papers by Hanxiang Zhan Breakdown of academic impact, for papers by Fuqing Hu Breakdown of academic impact, for papers by Estelle Saland Breakdown of academic impact, for papers by Barry Jutten Breakdown of academic impact, for papers by Wei Wei Prior Breakdown of academic impact, for papers by Guanghua Chen
Rankless by CCL
2026